European regulators say that Teva Pharmaceuticals and its Cephalon unit breached antitrust rules by agreeing to delay a cheaper generic version of the Provigil sleep-disorder pill from reaching consumers.
The findings, which are preliminary, refer to the same so-called pay-to-delay arrangement that, two years ago, prompted Teva to pay $1.2 billion to the U.S. Federal Trade Commission to settle allegations that the companies violated antitrust law.
About the Author Reprints
